Cervical cancer is the major cause of death from cancer in Africa. We wanted to assess the prevalence of human papillomavirus (HPV) infections and associated risk factors and to determine whether HPV testing could serve as a screening method for squamous intraepithelial lesions (SILs) in Rwanda. We also wanted to obtain a broader understanding of the underlying risk factors for the establishment of HPV infection in Rwanda.
Introduction
Cervical cancer is the most common cause of death from cancer in Africa, particularly in sub-Saharan Africa in countries such as Rwanda [1] . Chronic infection of the cervix uteri with human papillomavirus (HPV), particularly the HPV16 and HPV18 subtypes, may lead to the development of cervical low-grade and high-grade squamous intraepithelial lesions (LSILs and HSILs, respectively) and eventually to cancer [2] . In Rwanda, 8% of HIV-negative women and 32% of HIV-positive women are diagnosed with high-risk (HR)-HPV cervical infection [3] . Studies show that 9% of HIV-positive/HPV-positive women are diagnosed with HSILs [4] . HIV infection leads to an increased risk of chronic cervical HPV infection and a more rapid progression from LSILs and HSILs to cancer [5] . Hence, HIV infection is associated with a 50% increased risk of developing cervical cancer [6] . HPV infection may also predispose to HIV acquisition [7, 8] . The risk of developing cervical HR-HPV infection increases with the number of lifetime sexual partners and the smoking intensity [3, 9] . The risk is also higher in women with an early sexual debut and a history of using hormonal contraception [10] . Changes in the vaginal microbiota such as in bacterial vaginosis are associated with HR-HPV cervical infection [11] [12] [13] . Coinfections with sexually transmissible infections (STIs) such as Trichomonas vaginalis are associated with HPV infection [14] . Infection with Chlamydia trachomatis may also increase the risk of developing cervical cancer [15] . To date, beside HIV, how coinfections affect the risk of developing HPV infection has not been studied in Rwanda.
Rwanda was the first country in Africa to massvaccinate schoolgirls in 2011 [16] . The current vaccination targets HPV16 and HPV18 and the low-risk (LR) HPV strains HPV6 and HPV11 [16] . There is, however, a great heterogeneity in HR-HPV strains causing cervical infections in Rwanda [17] , which may lead to incomplete protection against HPV. Moreover, Pap smear tests and visual inspection with acetic acid (VIA) tests are not performed systematically in the country, and the number of trained oncologists, cancer surgeons and pathologists is low [1] . In view of the delay in the effect of the vaccination programme on the cervical cancer incidence and the possibility that strains other than HPV16 and HPV18 contribute to the cervical cancer incidence, it is of importance to find easy and accessible ways to screen women to identify those at risk of developing cervical cancer.
We wanted to further elucidate why cervical cancer is responsible for the majority of deaths from cancer in Rwanda. In our study, in a cohort of HIV-positive women and a cohort of HIV-negative women in Rwanda, we assessed (1) the prevalence of HPV infection and premalignant cervical lesions, (2) whether screening for HR-HPV might be suitable to identify women at risk of developing cervical cancer, (3) whether the currently used HPV vaccine covers the HPV strain profile of Rwanda and (4) the prevalence of coinfections and risk factors for HPV infection and cytological abnormalities.
Methods
Between July and October 2015, women ≥ 18 years old were enrolled in the study. Those recruited at the public antiretroviral treatment clinic at the University Teaching Hospital of Kigali (UTHK) were included in the HIV-positive group. Those recruited at the out-patient gynaecology and obstetric clinics at UTHK and at the University Teaching Hospital in Butare (UTHB) were tested for HIV; those who tested positive were included in the HIV-positive group, and those who tested negative constituted the HIVnegative group. Exclusion criteria were pregnancy, a history of HPV infection and/or cervical cancer, presenting any known concurrent disease likely to limit life expectancy to < 24 months and presenting any other factor suggesting inability to comply with the study protocol. In our study, 206 HIV-positive women, 172 HIV-negative women and 22 women with unknown HIV status were recruited. Participants were interviewed by a nurse in Kinyarwanda (the national Rwandan language) and data covering sociodemographic status, sexual behaviour, history of STIs, obstetric and gynaecological history and risk factors for cervical cancer were recorded in a database.
ThinPrep Pap test and HPV screening
The women underwent a gynaecological examination and a sample from the cervix was taken with an endocervical brush (Hologic Inc., Marlborough, MA, USA), a broom like collection device. The brush was rinsed and the sample stored in PreservCyt (Hologic Inc.) transport medium. Two millilitres of solution were transferred to a second tube for a 37-HPV screening test (Hologic Inc.) (Appendix S1), while the remaining solution was used for a ThinPrep Pap test (Appendix S1). Women diagnosed with HSILs and cancer were referred to the gynaecology departments at UTHK and UTHB for a VIA test and further medical interventions according to the Rwanda screening algorithm. Women with other cytological abnormalities were invited to participate in a follow-up study consisting of a second cervical specimen collection 9 months after initial recruitment. The results of the ThinPrep Pap test were reported according the 2001 Bethesda System (Appendix S1) [18] . Subjects with unsatisfactory results (not determined) were considered to have abnormal results in the analyses. group were also tested for hepatitis B virus, hepatitis C virus, syphilis, candidiasis, trichomoniasis and bacterial vaginosis (Appendix S1).
Ethical considerations
The project was approved by the Institutional Review Board at the College of Medicine and Health Sciences, University of Rwanda and by the Ethics Committee at the University of Gothenburg, Gothenburg, Sweden.
Statistics
All statistical tests were two-sided and considered significant when P-values were < 0.05. Pearson's v 2 test or Fisher's exact test for categorical data was used when comparing participants categorized by HIV status and age. Univariate logistic regression analysis was performed to generate odds ratios (ORs) with 95% confidence intervals (CIs) for each variable and its association with HPV infection or LSILs/HSILs/cancer. Variables with a univariate Pvalue < 0.05 were entered in the multivariate logistic regression analysis by the enter method and adjusted odds ratios (AORs) were then determined. As HIV-positive women were on average older than HIV-negative women, the two cohorts were also stratified according to age in order to be able to identify any changes over time.
Results

Characterization of the study population in relation to HIV infection status
The mean age was 46 AE 8 years (mean AE standard deviation) in the HIV-positive group and 40 AE 10 years in the HIV-negative group (P < 0.001; n = 206 and 172, respectively). Education levels were similar in the HIV-positive and HIV-negative groups (Fig. 1a) . The percentage of women who were widows was much higher in the HIV-positive group than in the HIV-negative group (P < 0.001; 56.8% vs 12. 7% Fig. 1b) . The numbers of live births and abortions were similar in the HIV-positive and HIV-negative groups (Fig. 1c,d ). The number of live births decreased with age in both HIV-positive and HIV-negative women (Fig. 1c) . In the HIV-positive group, it was more common to have had a sexual debut before the age of 16 years, while in the HIV-negative group it was more common to have had a sexual debut after the legal age of marriage of 21 years (P < 0.01; 52.1% vs. 30. 2% Fig. 1e ). Consistent with this, 61% of HIV-negative women reported only one lifetime sexual partner compared with 27% in the HIVpositive group (P < 0.001; Fig. 1f ). The proportion of participants who had never used an intrauterine device or hormonal contraceptives was similar among HIVpositive women and HIV-negative women and between age groups (Fig. 1g, h ). The proportion of women who had ever smoked was similar in HIV-positive and HIVnegative women. Of note, while being a current smoker or ex-smoker was common among elderly women, it was very uncommon to smoke among younger women (Fig. 1i) .
CD4 count and viral load in HIV-positive women
Six women recruited at the out-patient clinics tested positive for HIV (i.e. 2.9%). Close to 90% of HIV-positive women had been diagnosed with HIV infection for at least 6 years and close to 90% were on antiretroviral therapy (ART) (Fig. S1 ). Only 4% of HIV-positive women had a CD4 count of < 200 cells/lL and > 80% had an HIV viral load stabilized at < 400 HIV-1 RNA copies/mL (Fig. S1 ).
Attitudes to cervical cancer screening tests
In the HIV-negative group, only 7% of women had undergone a cervical cancer screening test before the study. The proportion was higher in the HIV-positive group, but still only 27% (P < 0.001; Fig. 2a ). The most common reason for women to have undergone a screening test was a recommendation by their physicians to do so. This was more often reported in the HIV-positive group, while HIV-negative women reported more frequently that the idea to take the test was their own (Fig. 2b) . The most common reason not to have undergone a cervical cancer screening test was lack of information about the test and/or cervical cancer. HIV-positive women reported more frequently than HIV-negative women that they had not undergone a previous screening test for financial reasons (25% vs. 7%, respectively; P < 0.001; Fig. 2c ). Forty-seven percent of HIV-negative women reported that they had been informed about the study by their acquaintances or by their health care providers (Table 1) .
Concomitant infections in HIV-positive and HIV-negative women
The frequency of T. vaginalis infection decreased with age in the HIV-positive group, while it increased with age in the HIV-negative group (Fig. 2g) . Candida albicans was the most prevalent genital infection and the prevalence decreased with age in both HIV-positive and HIVnegative women (Fig. 2h) . Syphilis infection and bacterial vaginosis occurred rarely among HIV-positive and HIVnegative women. However, bacterial vaginosis was more prevalent (P < 0.001) and syphilis tended to be more prevalent among HIV-negative than HIV-positive women (Fig. 2i ). Women were also asked if they had had a genital gonorrhoea or chlamydia infection in the past. The percentage of women who had ever been infected with gonorrhoea was higher in the HIV-positive group compared with the HIV-negative group (P < 0.001) and the percentage increased with age ( Fig. 2j) . Only a few women reported having been infected with chlamydia, although the proportion who stated "I don't know" was much higher in the HIV-positive group than in the HIVnegative group (P < 0.001; Fig. 2k ). The percentages of women who tested positive for hepatitis B virus surface antigen (HBsAg) and hepatitis C virus (HCV)-specific antibodies were small in both HIV-positive women (1.0 and 2.1%, respectively) and HIV-negative women (3.4 and 2.6%, respectively; Fig. 2l ).
HPV strains and cytological abnormalities among HIV-positive and HIV-negative women
The prevalence of being infected with HPV was higher in the HIV-positive group than in the HIV-negative group (27.7 and 11.6%, respectively; P < 0.001; Table 2 and Fig. 2d) . A variety of different HPV strains were detected in the two cohorts. Possibly high-risk (PHR)/HR-HPV infections were more common in the HIV-positive group than in the HIV-negative group (21.4 and 8.1%, respectively; P < 0.01; Table 2 ). Moreover, the prevalence of being infected with multiple HPV strains was much higher in the HIV-positive group than in the HIV-negative group (9.2 vs. 1.7%, respectively; P < 0.001; Table 2 ). The most common HR-HPV strains were HPV16 (4.3%) and HPV52 (4.3%), which constituted 39.7% of all HPV infections. HPV18 was only found in three of 400 participants ( Table 2 ). The percentage of women infected with PHR/ HR-HPV strains decreased with age in both the HIVpositive and HIV-negative groups (Fig. 2d) . Similarly, the percentage of women presenting cytological abnormalities decreased with age in both the HIV-positive and HIV-negative groups (Fig. 2e) . Cytological abnormalities were observed in 24.3% of HIV-positive women and in 9.9% of HIV-negative women (P < 0.001; n = 206 and 171, respectively; Table 2 and Fig. 2e ). LSILs and HSILs/squamous cell carcinoma (SCC) were diagnosed in 3.4 and 5.8%, respectively, of HIV-positive women and in 4.7 and 1.2%, respectively, of HIV-negative women ( Fig. 2f and Table 2 ). The sensitivity and specificity to detect HSILs or worse with HPV screening were 0.78 and 0.87, respectively (Table 2) .
Participants' characteristics associated with PHR/HR-HPV infection and squamous intraepithelial lesions
Among HIV-negative women, being divorced was positively associated with PHR/HR-HPV infection (OR 6.48; 95% CI 1.40-29.93; P < 0.05; Table 3 ). Among HIVpositive women, ever having had a genital gonorrhoea infection (OR 4.88; 95% CI 2.20-10.82; P < 0.001; AOR 3.01; 95% CI 0.88-10.24; P = 0.07) and not knowing if they had been infected with chlamydia in the past (OR 3.00; 95% CI 1.48-6.05; P < 0.01; AOR 2.61; 95% CI 0.79-8.64; P = 0.12) were positively associated with PHR/ (Tables 3 and 4 ). Being on ART was negatively associated with PHR/HR-HPV infection (OR 0.20; 95% CI 0.05-0.70; P < 0.05) and a CD4 count > 500 cells/lL tended to be negatively associated with PHR/HR-HPV infection (OR 0.26; 95% CI 0.05-1.28; P = 0.09; AOR 0.18; 95% CI 0.03-1.03; P = 0.05; Tables 3 and 4) .
HR-HPV infection
Among HIV-negative women, being infected with HBV (OR 18.80; 95% CI 2.54-138.80; P < 0.01; AOR 50.25; 95% CI 2.86-882.34; P < 0.01), with T. vaginalis (OR 6.71; 95% CI 1.14-39.46; P < 0.05; AOR 30.98; 95% CI 2.03-472.58; P < 0.05) and with PHR/HR-HPV (OR 16.89; 95% CI 4.12-69.19; P < 0.001; AOR 16.33; 95% CI 3.28-81.34; P < 0.001) were positively associated with SILs (Tables 3  and 4 ). Among HIV-positive women, the number of live births (OR 1.44; 95% CI 1.12-1.85; P < 0.01; AOR 1.55; 95% CI 1.12-2.17; P < 0.05) and being infected with PHR/ HR-HPV (OR 14.65; 95% CI 4.91-43.72; P < 0.001; AOR 13.02; 95% CI 3.52-48.16; P < 0.001) were positively associated with SILs, while being on ART (OR 0.14; 95% CI 0.03-0.55; P < 0.01) and having a CD4 count > 500 cells/ lL (OR 0.07; 95% CI 0.01-0.55; P < 0.05; AOR 0.31; 95% CI 0.02-3.63; P = 0.35) were negatively associated with SILs (Tables 3 and 4 ).
Discussion
Our study shows that great heterogeneity exists in HPV strains infecting Rwandan women, with an almost threefold higher HPV prevalence in the HIV-positive compared with the HIV-negative group. Coinfection with multiple HPV strains was also common, particularly in the HIVpositive group. Our data show that 21% of HIV-positive and 8% of HIV-negative women were infected with PHR/ HR-HPV. The prevalence of PHR/HR-HPV infection among HIV-positive women was lower than the 32-34% reported previously in Rwanda [3, 17] . However, our cohorts consisted of an older population of women (89% were ≥ 35 years old) who were from different regions of Rwanda, which may have contributed to the difference in HPV prevalence.
Heterogeneity of HPV strains
Among HPV-positive women, the most common HPV strains were HPV16 (21.8%) and HPV52 (21.8%). HPV18 occurred in 5.1% of HPV-positive women, in accordance with previous prevalence figures from Rwanda [17] . The current vaccine used in Rwanda (Gardasil â Merck & Co., Inc., Whitehouse Station, NJ, USA) protects against HPV16, HPV18, HPV6 and HPV11. The vaccine also may give cross-protection against HPV33, HPV31, HPV45, and HPV51 [19] . In view of HPV52 being prevalent in Rwanda, while HPV16 and HPV18 are much less common than in Europe and the USA, our data indicate that the present vaccine may give insufficient coverage against cervical cancer. The introduction of a vaccine with broader HPV coverage, such as the nonavalent vaccine Gardasil â 9, into the vaccination programme in future may therefore be of particular importance in Rwanda. In line with previous reports [20] , HIV-positive women were more commonly infected with multiple HPV strains than HIV-negative women, specifically with multiple HR-HPV infections. Studies suggest that patients with multiple HR-HPV infections are more likely to have chronic LSILs [21] . Multiple HPV strains are also more common in those with HSILs than in those with LSILs [22] . Multitype HPV infections have been shown to be associated with larger cervical lesions [23] .
STIs and genital infections common in the study population HIV-positive women had an earlier sexual debut and more sexual partners than HIV-negative women. Still, the reported number of sexual partners was low. Whether women were living with polygynous partners was not covered in our questionnaire, which could have affected our results. STIs were more common among HIV-positive women, although the women did not always know which type of infection they had. Candida albicans colonization was more common in HIV-positive women than in HIV-negative women, and our prevalence figures are similar to those reported from Burkina Faso and Kenya [20, 24, 25] . Our study revealed a higher prevalence of syphilis among HIVnegative women than previous studies [26] . The seroprevalence of syphilis was 6% in HIV-negative women and 2% in HIV-positive women. Even considering the small number of identified cases (six of 100) among HIV-negative women, the seroprevalence of syphilis was markedly higher than the prevalence of 0.8% reported in the recently published study from Rwanda by Mutagoma et al. [26] .
Economical reasons for not undergoing cervical screening among HIV-positive women
In view of HIV being a risk factor for cervical cancer, it is notable that only 27.7% of HIV-positive women had previously undergone cervical cancer screening. Among both HIV-positive and HIV-negative women, a high proportion of women were not aware of the test. About two-third of the cohorts were not aware of the cervical cancer screening test, which is lower than in countries such as Kenya and Uganda [27, 28] . A large proportion of HIV-positive women reported economical reasons for not undergoing cervical cancer screening, which is commonly reported in developing countries [29] . Being widowed was more common among HIV-positive women than HIV-negative women, which probably contributes to a worse economic situation, where health care issues may not be prioritized. Studies from Rwanda's neighbour, the Democratic Republic of Congo, show that less than one-third of women are willing to pay for a Pap smear test [30] . Information campaigns about cervical cancer targeting HIV-positive women are at present needed. Moreover, it is important to reduce the costs of undergoing cervical cancer screening, particularly for risk groups such as patients with HIV infection.
Risk factors associated with HPV infection and SILs
Of women recruited in out-patient gynaecology clinics, 2.9% were diagnosed with HIV infection, in line with previously reported prevalence figures in Rwanda [31] . Most women at the HIV clinic at UTHK were on ART, had normal CD4 counts and had low viral loads. The percentage of HIV-positive patients on ART has increased significantly in recent years, and in 2015 the percentage was 79% [32] . HIV-positive women on ART and with a normal CD4 count had a decreased risk of being infected with HPV and being diagnosed with SILs, which is consistent with previous studies [33, 34] . Still, the prevalence of HPV was higher in the group of well-treated HIV-positive women compared with the HIV-negative women.
ART increases the chance of clearing HPV infections; however, some HR-HPV may still be difficult to eradicate on ART [35] . Even in HIV-positive patients on ART with a normal CD4 count, HPV-specific T-cell immunity may be impaired, contributing to the difficulty in clearing HPV infections [36] . Previous STIs and genital infections increased the risk of HPV infection among both HIV-positive and HIV-negative women. HIV-positive women have a higher degree of susceptibility to various genital infections and may be exposed to more genital infections than HIV-negative women [37] . We found that multiparity was associated with SILs among HIV-positive women, which is supported by previous reports [38] . Pregnancy leads to immunosuppression, which may facilitate HPV infection and the generation of HSILs [39] . Although the number of positive cases of hepatitis B was low in our study, our data indicate that being infected with HBV may be associated with the presence of SILs. An association between hepatitis B and cervical HPV infection has been demonstrated previously [40] . Both infections may be transferred sexually, and the immunological characteristics of the patients may also make them more prone to viral infections and viral coinfections.
HPV screening test to identify women with HSILs
Our data show that HR/PHR-HPV screening had a relatively high sensitivity (78%) and specificity (87%) for detecting HSILs and cancer. HPV screening compared with cytology increases the sensitivity to detect HSILs, but with the cost of less specificity [41] . The combination of HPV screening and cytology may improve cervical cancer screening [42] . The character of screening needs, however, to be put in the context of health care resources. Health care resources are scarce in Rwanda and the number of gynaecologists and pathologists working in the country is low. Therefore, there is a need to find ways of screening women to identify those at risk of HSILs and cervical cancer without overloading the health care system. HPV screening could perhaps be used particularly in high-risk individuals, such as patients with HIV infection, other immunodeficient patients and sex workers.
Limitations
The HIV-positive group was older than the HIV-negative group, which could have affected the percentage infected with HPV and presenting premalignant lesions. Moreover, participants in the HIV-negative group contacted the research team to be included in the study, while participants in the HIV-positive group were asked to participate during a pre-scheduled clinical examination. Hence, the percentage presenting symptoms in the genital tract could have been higher in the HIV-negative group than in the HIV-positive group, which as a consequence could have affected the percentage with genital infections.
Conclusions
HPV infection and coinfection with other STIs are common in Rwanda, particularly in patients with HIV infection. Our study lends support to implementation of the HPV screening test to identify women at risk of developing cervical cancer. The current quadrivalent vaccine may not give satisfactory coverage against HR-HPV infections in Rwanda.
